PMID: 11328289May 1, 2001Paper

Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol

British Journal of Haematology
I M HannUK Medical Research Council's Working Party on Childhood Leukaemia

Abstract

The single most important prognostic determinant in childhood acute lymphoblastic leukaemia (ALL) is effective therapy and changes in therapy may influence the significance of other risk factors. The effect of intensified therapy on the importance of currently recognized phenotypic and genotypic determinants of outcome was assessed in 2090 children enrolled on the Medical Research Council United Kingdom acute lymphoblastic leukaemia XI (MRC UKALL XI) protocol. Treatment allocation was not determined by risk factors. Multivariate analysis confirmed the dominant influence on prognosis of age, sex and presenting white cell count (WCC). After allowing for these features, blast karyotype, d 8 marrow blast percentage and remission status at the end of induction therapy were the only remaining significant predictors of outcome. Organomegaly, haemoglobin concentration, French--American--British type, body mass index, presence of central nervous system disease at diagnosis, immunophenotype and presence of TEL/AML1 fusion gene (examined in a subset of 659 patients) either had no significant effect on outcome or were significant only in univariate analysis. Among karyotype abnormalities with an independent influence on prognosis, high hyp...Continue Reading

References

Jan 1, 1992·Leukemia Research·B W Baker, J D Norton
Dec 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MillerG D Hammond
Feb 1, 1995·British Journal of Haematology·J M ChessellsO B Eden
Oct 1, 1994·Archives of Disease in Childhood·M B VianaW S Silvestrini
Nov 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P S GaynonG H Reaman
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D G TubergenG D Hammond
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M SmithR Ungerleider
May 9, 1996·The New England Journal of Medicine·J T SandlundW M Crist
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P G SteinherzW A Bleyer
Mar 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J E RubnitzF G Behm
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F M UckunN A Heerema
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C H PuiW E Evans

❮ Previous
Next ❯

Citations

May 1, 2012·Annals of Hematology·MacGregor Steele, Aru Narendran
Jan 22, 2004·Cancer Genetics and Cytogenetics·Rachel L HarrisAnthony V Moorman
Jul 26, 2002·British Journal of Haematology·Judith M ChessellsUNKNOWN Medical Research Council Working Party On Childhood Leukaemia
Aug 30, 2002·British Journal of Haematology·Tim Eden
Aug 30, 2002·British Journal of Haematology·Athanasios B-T FassasGuido Tricot
Aug 28, 2002·Reviews in Clinical and Experimental Hematology·Stefan FaderlHagop M Kantarjian
Apr 16, 2002·Current Problems in Pediatric and Adolescent Health Care·Ka Wah Chan
Apr 17, 2004·Journal of Pediatric Hematology/oncology·Eduard H PanosyanUNKNOWN Children's Cancer Group Study CCG-1961
Jun 4, 2002·Current Opinion in Hematology·Mignon L Loh, Jeffrey E Rubnitz
Sep 25, 2001·Archives of Disease in Childhood·J M ChessellsI M Hann
Nov 4, 2010·Indian Journal of Pathology & Microbiology·Safoorah KhalidMohammad Khurshid
Sep 7, 2005·Pharmacogenomics·Wee J Chng, Rafael Fonseca
Jul 28, 2015·Expert Review of Anticancer Therapy·Marc De BraekeleerNathalie Douet-Guilbert
Jul 14, 2010·Cancer Genetics and Cytogenetics·Rubina SiddiquiRobert Carr
Jan 27, 2009·Cancer Genetics and Cytogenetics·Lea A WehrliJean-Pierre Bourquin
Dec 23, 2008·Cancer Genetics and Cytogenetics·Paulo R G ZenGiorgio A Paskulin
Jan 22, 2008·Cancer Genetics and Cytogenetics·Alice FabariusPeter Duesberg
Apr 1, 2008·The Lancet Oncology·Kathy Pritchard-JonesMaria Grazia Valsecchi
Aug 16, 2005·British Journal of Haematology·Louise K Jones, Vaskar Saha
Jun 15, 2005·British Journal of Haematology·C D MitchellUNKNOWN Medical Research Council Childhood Leukaemia Working Party
Jun 15, 2005·British Journal of Haematology·Jonathan BuryVaskar Saha
Apr 2, 2005·British Journal of Haematology·Anindita RoyUNKNOWN Medical Research Council Childhood Leukaemia Working Party
May 19, 2004·British Journal of Haematology·Christine J HarrisonUNKNOWN Childhood and Adult Leukaemia Working Parties
Nov 18, 2003·British Journal of Haematology·Judith M ChessellsIan M Hann
Feb 5, 2008·British Journal of Haematology·Erik ForestierUNKNOWN NOPHO Leukaemia Cytogenetic Study Group (NLCSG)
Mar 4, 2008·Genes, Chromosomes & Cancer·Doris SteinemannBrigitte Schlegelberger
Dec 23, 2004·Seminars in Cancer Biology·Manuel R Teixeira, Sverre Heim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.